Revolution Medicines shared Phase III clinical trial results for a pill called daraxonrasib in patients with previously ...

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival -- Company intends to include these data in a future New Drug Application submission to the ...

The subject of buyout rumors this year, Revolution posted Phase 3 results one analyst called a “game changer” in a ...

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

Co-primary efficacy in RAS G12–mutant PDAC included statistically significant OS and PFS gains assessed by blinded ...

Mutations in a protein called KRAS fuel some of the most lethal cancers. Designing drugs to disable KRAS has proved ...

As we age, our cells accumulate genetic changes—mutations—some of which open the door to cancer. Scientists call these ...

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to ...

Researchers at the MRC Laboratory of Medical Sciences (LMS) and Imperial College London have identified an overworked cog in ...

Today, doctors are increasingly looking at the genetic makeup of each patient’s tumor to guide treatment decisions.